# Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

> **NCT04089267** · PHASE4 · COMPLETED · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 288 (actual)

## Conditions studied

- ITP

## Interventions

- **DRUG:** TPO

## Key facts

- **NCT ID:** NCT04089267
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-12
- **Final completion:** 2019-08
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2019-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089267, "Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04089267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*